A Phase I Trial of AMG 386 and Temsirolimus in Advanced Solid Tumors With an Expansion Cohort in Uterine Cancer, Renal Cell Carcinoma and Carcinoid Tumors
Phase of Trial: Phase I
Latest Information Update: 19 Dec 2015
At a glance
- Drugs Trebananib (Primary) ; Temsirolimus
- Indications Carcinoid tumour; Renal cell carcinoma; Solid tumours; Uterine cancer
- Focus Adverse reactions
- 19 Dec 2015 Results published in the Investigational New Drugs
- 05 Oct 2015 Status changed from discontinued to completed as reported by ClinicalTrials.gov.
- 02 Mar 2015 Planned primary completion date changed from 1 Feb 2015 to 1 Sep 2015, as reported by ClinicalTrials.gov.